OncoMatch/Clinical Trials/NCT05704621
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Is NCT05704621 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies chemotherapy for ovarian cancer.
Treatment: chemotherapy — This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Prior therapy
Must have received: platinum-based chemotherapy
platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer; Progression-free interval of at least 6 months after end of last platinum- containing therapy
Must have received: PARP inhibitor — maintenance
Progressed during PARP inhibitor maintenance
Cannot have received: chemotherapy
Exception: one prior chemotherapy allowed
More than one prior chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify